{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aeterna Zentaris Inc."},"Symbol":{"label":"Symbol","value":"AEZS"},"Address":{"label":"Address","value":"C/O NORTON ROSE FULBRIGHT CANADA, LLP 222 BAY STREET, TORONTO, Ontario, M5K 1E7, Canada"},"Phone":{"label":"Phone","value":"+1 843 900-3223"},"Industry":{"label":"Industry","value":"Pharmaceuticals and Biotechnology"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"AEterna Zentaris Inc is a biopharmaceutical company commercializing &amp; developing therapeutics &amp; diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk &amp; the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. &amp; Canada. It is leveraging the clinical success &amp; safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland."},"CompanyUrl":{"label":"Company Url","value":"https://www.zentaris.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Klaus Wolfgang Paulini","title":"President, Chief Executive Officer &amp; Director"},{"name":"Michael Teifel","title":"Chief Scientific Officer &amp; Senior Vice President"},{"name":"Nicola Ammer","title":"Chief Medical Officer &amp; Senior Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}